Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07662109 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT07662109 is a Phase 3 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 2,000 participants.
The verdict
NCT07662109, a Phase 3 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Interventions
- DRUG Dapagliflozin
- DRUG Elecoglipron
- DRUG Elecoglipron-matched placebo
- DRUG Dapagliflozin-matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-07-06 |
| Est. Completion | 2028-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07662109
The ClinicalTrials.gov registry entry for NCT07662109 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT07662109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07662109 about?
NCT07662109 is a clinical study titled "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated w...
What is the current status of trial NCT07662109?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2026-07-06. Estimated completion is 2028-07-05.
What interventions are being tested in trial NCT07662109?
The interventions under investigation include: Dapagliflozin (DRUG), Elecoglipron (DRUG), Elecoglipron-matched placebo (DRUG), Dapagliflozin-matched placebo (DRUG).
Who is sponsoring clinical trial NCT07662109?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.